Tag - Myomo

Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

Antonette Ho2024-01-23T22:49:34-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase anRead more >>

Myomo to raise $6M with eyes on Medicare coverage

Antonette Ho2024-01-18T20:39:27-05:00Myomo announced today that it entered into securities purchase agreements worth approximately $6 million. The company entered into agreements with certain new and existing institutional investors, plus insiders at Myomo. This agreement includes nearly 1.6 million shares of common stock priced at $3.80 per share. In conjunction with the offering, Myomo disclosed that it expects existing cash plus proceeds to help achieve cash flow breakeven on a quarterly basis. The company anticipates realizing this by the fourth quarter of 2024....

Myomo Announces Closing of $4.4 Million Public Offering

Antonette Ho2023-09-01T00:41:41-04:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds...

Myomo’s (MYO) MyoPro Seeks CMS Classification for Medicare Cover

Antonette Ho2023-07-11T01:21:56-04:00Myomo, Inc. recently achieved a significant milestone with its MyoPro device. The company's request to the Centers for Medicare and Medicaid Services (CMS) to reclassify the MyoPro as a brace has been published for public comment. Myomo is a pioneering wearable medical robotics company catering to individuals with neurological disorders and upper-limb paralysis. With this development, the company advances with its target to support health equity for medically-qualified Medicare Part B beneficiaries. At present, MyoPro is categorized as durable medical...

Myomo Reports Fourth Quarter and Full Year 2022 Financial Result

Antonette Ho2023-03-24T16:03:19-04:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022. inancial and operational highlights for the fourth quarter of 2022 include the following: Product and total revenues were $4.0 million, up 2% sequentially and similar to the prior year quarter; Revenue units were 101, up 16% sequentially and down 6% compared with the prior year...

MyoPro Approved in Australia by National Disability Insurance Scheme

Antonette Ho2023-02-14T20:02:04-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids over 500,000 Australians with disabilities through reimbursement for necessary services and support. The patented MyoPro technology was developed by Myomo in collaboration with researchers at the Massachusetts Institute of Technology and Harvard Medical...

Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

Antonette Ho2023-02-14T19:58:41-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. “We welcome Yitz to the Myomo Board of Directors and are gratified that AIGH was the lead investor in our most recent equity offering,” said Paul R. Gudonis,...

Myomo Announces Closing of $6.5 Million Upsized Public Offering

Antonette Ho2023-01-18T01:38:35-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. Read more >>

Myomo Announces Pricing of $6.5 Million Upsized Public Offering

Antonette Ho2023-01-17T00:34:18-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or...

Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial

Ziad2022-11-25T13:59:44-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro® units from Cleveland’s Louis Stokes Veterans Administration (“VA”) Medical Center. The primary objective of this trial is to study the efficacy of the MyoPro in motor learning-based therapy for individuals with chronic stroke (>6 months post event) with severe upper limb motor deficits (Fugl-Meyer for Upper Limb score less than 30),...